Form 4: Glaukos Director Receives Equity Compensation Grant

Director David F. Hoffmeister was granted restricted stock units and stock options as part of the Glaukos Corporation director compensation policy.

Summary

• Director David F. Hoffmeister acquired 1,878 restricted stock units (RSUs) on May 28, 2026.
• The director was also granted 2,987 stock options with an exercise price of $53.57.
• The RSUs and options were issued under the company's standard Director Compensation Policy.
• Following the transaction, the director holds 49,549 shares directly and 38,176 shares indirectly through Sentinel Point Partners, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation with no impact on company operations or financial health.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standardized compensation structure indicates stable corporate governance practices.

Negatives

• None identified; this is a routine disclosure of director compensation.

Risks

• None identified; this is a routine disclosure of director compensation.

Future Outlook

The equity grants are subject to a one-year vesting period, aligning the director's tenure with long-term company performance.

Management Comments

• The transactions were executed pursuant to the Issuer's Director Compensation Policy.

Industry Context

StockSavvy.ai notes that routine equity grants to board members are standard practice in the medical device industry to ensure long-term alignment between leadership and shareholder value.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is consistent with standard corporate governance practices for mid-cap medical technology companies.
• The one-year vesting schedule is typical for non-employee director compensation plans.

Stakeholder Impact

• Minimal impact on shareholders as these are standard compensation grants.

Next Steps

• Vesting of restricted stock units on May 28, 2027.
• Vesting of stock options on May 28, 2027.

Key Dates

Keywords

Glaukos, GKOS, Form 4, Director Compensation, Insider Trading, Equity Grant